Pfizer Inc. (PFE): Price and Financial Metrics
PFE Price/Volume Stats
| Current price | $29.62 | 52-week high | $34.11 |
| Prev. close | $29.75 | 52-week low | $25.20 |
| Day low | $29.52 | Volume | 17,265,754 |
| Day high | $30.35 | Avg. volume | 37,804,227 |
| 50-day MA | $29.34 | Dividend yield | 5.59% |
| 200-day MA | $28.13 | Market Cap | 167.84B |
PFE Stock Price Chart Interactive Chart >
Pfizer Inc. (PFE) Company Bio
Pfizer Inc. is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products. Pfizer was founded under its original name, Charles Pfizer & Company, in 1849 in Brooklyn, New York by Charles Pfizer and Charles Erhart. The company operates research and development facilities in United States and the United Kingdom and employs over 78,000 individuals worldwide. Some of the company’s more recognizable brands include Advil, Celebrex, Chantix, Chapstick, Dimetapp, Lipitor, Robitussin, and Viagra. Albert Bourla serves as Pfizer’s Chairman of the Board and Chief Executive Officer and the company is headquartered in New York, New York.
Latest PFE News From Around the Web
Below are the latest news stories about PFIZER INC that investors may wish to consider to help them evaluate PFE as an investment opportunity.
The 500 Top Stocks to Buy for 2024, Ranked by AIThese are the very best stocks to buy for 2024 for any investor, according to Tom Yeung's MarketMasterAI system. |
Top Performers: 7 High-Efficiency Stocks With Stellar Profit Per Employee RatiosInundated with myriad ways of assessing publicly traded companies, one unique metric could intrigue investors seeking opportunities in 2024 and that would be high-efficiency stocks. |
Interested in the Weight-Loss Market? Here's 1 Stock to Buy Hand Over Fist in 2024, and 1 to Avoid Like the Plague.While Novo Nordisk dominates the weight-loss market, there are two other stocks to consider as well. |
S&P 500 Is Nearing a Record High. This Could Derail It in 2024.Microsoft and OpenAI are sued by the New York Times for copyright infringement, Amazon plans to launch adverts on Prime Video next month, and other news to start your day. |
Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?COVID-19 products Comirnaty and Paxlovid are no longer Pfizer's crown jewels. But that's OK. |
PFE Price Returns
| 1-mo | 2.49% |
| 3-mo | 9.82% |
| 6-mo | 13.03% |
| 1-year | -5.38% |
| 3-year | -22.68% |
| 5-year | 6.45% |
| YTD | 9.03% |
| 2023 | -41.26% |
| 2022 | -10.41% |
| 2021 | 66.69% |
| 2020 | 3.23% |
| 2019 | -6.91% |
PFE Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching PFE
Want to see what other sources are saying about Pfizer Inc's financials and stock price? Try the links below:Pfizer Inc (PFE) Stock Price | Nasdaq
Pfizer Inc (PFE) Stock Quote, History and News - Yahoo Finance
Pfizer Inc (PFE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...